REGN
Regeneron Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$827.72
−1.87%Margins
Gross margin
84.9%
EBITDA margin
37.0%
EBIT margin
25.6%
Net margin
27.9%
FCF margin
22.7%
13.7%
Return on equity
10.4%
Return on assets
11.8%
Return on invested capital
0.38x
Asset turnover
$4.4B
Cash from operations
$78
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026